A23V 2250/7046
Vitamin b3 niacin
Official title: Vitamin B3 niacin
A23V2250/7046 (Vitamin b3 niacin) appears on 8 US grants and 18 published applications in this corpus.
Search patents in A23V- Granted patents
- 8
- Published applications
- 18
- Assignees
- 8
- Inventors
- 18
- Latest grant
- 6 Jun 2023
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2016 | 0 | 1 |
| 2017 | 0 | 0 |
| 2018 | 0 | 3 |
| 2019 | 0 | 4 |
| 2020 | 3 | 3 |
| 2021 | 0 | 2 |
| 2022 | 3 | 2 |
| 2023 | 2 | 1 |
| 2024 | 0 | 1 |
| 2025 | 0 | 1 |
By publication year.
Recent patents
- Deuterated caffeine and uses thereof6 Jun 2023US 11,666,073 B2Lennham Pharmaceuticals, Inc.
- Deuterated caffeine and uses thereof10 Jan 2023US 11,547,127 B2Lennham Pharmaceuticals, Inc.
- Multivitamin extrudates22 Mar 2022US 11,278,046 B2Dsm IP Assets B.V.
- Antioxidant-enriched multivitamin composition and methods of use25 Jan 2022US 11,229,230 B2Callion Pharma, LLC
- Nutritional formulations and kits for bariatric individuals4 Jan 2022US 11,213,059 B2Mantra Pharma
- Deuterated caffeine and uses thereof7 Aug 2025US 2025/0248424 A1Lennham Pharmaceuticals, Inc.
- Deuterated caffeine and uses thereof29 Aug 2024US 2024/0284942 A1Lannham Pharmaceuticals, Inc,
- Deuterated caffeine and uses thereof23 Nov 2023US 2023/0371555 A1Lennham Pharmaceuticals, Inc.
- Deuterated caffeine and uses thereof11 Aug 2022US 2022/0248720 A1Lennham Pharmaceuticals, Inc.
- Deuterated caffeine and uses thereof21 Jul 2022US 2022/0225642 A1Lennham Pharmaceuticals, Inc.
Most cited
By later US patents
- Deuterated caffeine and uses thereof4US 10,582,716 B1Lennham Pharmaceuticals, Inc. · 2020
- Deuterated caffeine and uses thereof3US 10,765,130 B1Lennham Pharmaceuticals, Inc. · 2020
- Nutritional formulations using human milk oligosaccharides for modulating inflammation2US 10,624,916 B2Abbott Laboratories · 2020
- Multivitamin extrudates1US 11,278,046 B2Dsm IP Assets B.V. · 2022
- Deuterated caffeine and uses thereof1US 11,547,127 B2Lennham Pharmaceuticals, Inc. · 2023